{"generic":"Tirofiban Hydrochloride","drugs":["Aggrastat","Tirofiban Hydrochloride"],"mono":{"0":{"id":"jtims0","title":"Generic Names","mono":"Tirofiban Hydrochloride"},"1":{"id":"jtims1","title":"Dosing and Indications","sub":[{"id":"jtims1b4","title":"Adult Dosing","mono":"<ul><li><b>Acute coronary syndrome, Non-ST-Elevation:<\/b> 25 mcg\/kg IV within 5 minutes then 0.15 mcg\/kg\/min IV for up to 18 hours<\/li><li><b>Acute ST segment elevation myocardial infarction - Percutaneous coronary intervention:<\/b> Initial bolus, 25 mcg\/kg IV; maintenance infusion, 0.15 mcg\/kg\/min IV plus unfractionated heparin (guideline dosing)<\/li><li><b>Acute ST segment elevation myocardial infarction - Percutaneous coronary intervention:<\/b> Initial bolus, 10 mcg\/kg administered intracoronary  or IV  over 1 minute; maintenance infusion, 0.15 mcg\/kg\/min IV  for 24 to 36 hours (study dosing)<\/li><\/ul>"},{"id":"jtims1b5","title":"Pediatric Dosing","mono":"safety and efficacy not established in pediatric patients "},{"id":"jtims1b6","title":"Dose Adjustments","mono":"<ul><li><b>Renal impairment, CrCl less than 60 mL\/min:<\/b> 25 mcg\/kg IV within 5 minutes, then 0.075 mcg\/kg\/min IV up to 18 hours<\/li><li><b>Renal impairment, CrCl less than 30 mL\/min:<\/b> Reduce infusion by 50%<\/li><li><b>Geriatric:<\/b> No dose adjustment necessary<\/li><\/ul>"},{"id":"jtims1b7","title":"Indications","mono":"<b>FDA-Labeled Indications<\/b><br\/>Acute coronary syndrome, Non-ST-Elevation<br\/><b>Non-FDA Labeled Indications<\/b><ul><li>Acute ST segment elevation myocardial infarction - Percutaneous coronary intervention<\/li><li>Cerebrovascular accident<\/li><\/ul>"}]},"3":{"id":"jtims3","title":"Contraindications\/Warnings","sub":[{"id":"jtims3b9","title":"Contraindications","mono":"<ul><li>bleeding, active internal, or a history of bleeding diathesis, major surgery, or severe physical trauma within previous 30 days<\/li><li>hypersensitivity, severe (ie, anaphylaxis), to tirofiban<\/li><li>thrombocytopenia following prior tirofiban administration<\/li><\/ul>"},{"id":"jtims3b10","title":"Precautions","mono":"<ul><li>bleeding events, including fatalities, have been reported; typically at arterial access site; increased risk with concomitant use of fibrinolytics, oral anticoagulants, or antiplatelet drugs; minimize traumatic procedures (ie, punctures, intramuscular injections, nasotracheal intubation)<\/li><li>thrombocytopenia, profound, has been reported; previous glycoprotein IIb\/IIIa receptor antagonist exposure may increase risk; monitoring recommended; discontinue use if thrombocytopenia occurs<\/li><li>report suspected adverse events to the US Food and Drug Administration 1-800-FDA-1088 or www.fda.gov\/medwatch<\/li><\/ul>"},{"id":"jtims3b11","title":"Pregnancy Category","mono":"<ul><li>Tirofiban: B (FDA)<\/li><li>Tirofiban: B1 (AUS)<\/li><\/ul>"},{"id":"jtims3b12","title":"Breast Feeding","mono":"Tirofiban: Micromedex: Infant risk cannot be ruled out.<br\/>"}]},"4":{"id":"jtims4","title":"Drug Interactions","sub":[{"id":"jtims4b13","title":"Contraindicated","mono":"<ul>Eptifibatide (theoretical)<\/ul>"},{"id":"jtims4b14","title":"Major","mono":"<ul><li>Aceclofenac (theoretical)<\/li><li>Acemetacin (theoretical)<\/li><li>Alipogene Tiparvovec (theoretical)<\/li><li>Alteplase, Recombinant (theoretical)<\/li><li>Amtolmetin Guacil (theoretical)<\/li><li>Anagrelide (theoretical)<\/li><li>Apixaban (theoretical)<\/li><li>Ardeparin (theoretical)<\/li><li>Argatroban (theoretical)<\/li><li>Aspirin (probable)<\/li><li>Bivalirudin (theoretical)<\/li><li>Bromfenac (theoretical)<\/li><li>Bufexamac (theoretical)<\/li><li>Celecoxib (theoretical)<\/li><li>Certoparin (theoretical)<\/li><li>Choline Salicylate (theoretical)<\/li><li>Cilostazol (theoretical)<\/li><li>Citalopram (probable)<\/li><li>Clonixin (theoretical)<\/li><li>Dabigatran Etexilate (theoretical)<\/li><li>Dalteparin (theoretical)<\/li><li>Danaparoid (theoretical)<\/li><li>Desirudin (theoretical)<\/li><li>Desvenlafaxine (probable)<\/li><li>Dexibuprofen (theoretical)<\/li><li>Dexketoprofen (theoretical)<\/li><li>Diclofenac (theoretical)<\/li><li>Diflunisal (theoretical)<\/li><li>Dipyridamole (probable)<\/li><li>Dipyrone (theoretical)<\/li><li>Duloxetine (probable)<\/li><li>Edoxaban (theoretical)<\/li><li>Enoxaparin (theoretical)<\/li><li>Escitalopram (probable)<\/li><li>Etodolac (theoretical)<\/li><li>Etofenamate (theoretical)<\/li><li>Etoricoxib (theoretical)<\/li><li>Felbinac (theoretical)<\/li><li>Fenoprofen (theoretical)<\/li><li>Fepradinol (theoretical)<\/li><li>Feprazone (theoretical)<\/li><li>Floctafenine (theoretical)<\/li><li>Flufenamic Acid (theoretical)<\/li><li>Fluoxetine (probable)<\/li><li>Flurbiprofen (theoretical)<\/li><li>Fluvoxamine (probable)<\/li><li>Fondaparinux (theoretical)<\/li><li>Heparin (theoretical)<\/li><li>Ibuprofen (theoretical)<\/li><li>Ibuprofen Lysine (theoretical)<\/li><li>Indomethacin (theoretical)<\/li><li>Ketoprofen (theoretical)<\/li><li>Ketorolac (theoretical)<\/li><li>Lepirudin (theoretical)<\/li><li>Levomilnacipran (theoretical)<\/li><li>Lornoxicam (theoretical)<\/li><li>Loxoprofen (theoretical)<\/li><li>Lumiracoxib (theoretical)<\/li><li>Meclofenamate (theoretical)<\/li><li>Mefenamic Acid (theoretical)<\/li><li>Meloxicam (theoretical)<\/li><li>Milnacipran (probable)<\/li><li>Morniflumate (theoretical)<\/li><li>Nabumetone (theoretical)<\/li><li>Nadroparin (theoretical)<\/li><li>Naproxen (theoretical)<\/li><li>Nefazodone (probable)<\/li><li>Nepafenac (theoretical)<\/li><li>Niflumic Acid (theoretical)<\/li><li>Nimesulide (theoretical)<\/li><li>Oxaprozin (theoretical)<\/li><li>Oxyphenbutazone (theoretical)<\/li><li>Parecoxib (theoretical)<\/li><li>Parnaparin (theoretical)<\/li><li>Paroxetine (probable)<\/li><li>Phenindione (theoretical)<\/li><li>Phenprocoumon (theoretical)<\/li><li>Phenylbutazone (theoretical)<\/li><li>Piketoprofen (theoretical)<\/li><li>Piroxicam (theoretical)<\/li><li>Proglumetacin (theoretical)<\/li><li>Propionic Acid (theoretical)<\/li><li>Propyphenazone (theoretical)<\/li><li>Proquazone (theoretical)<\/li><li>Protein C (theoretical)<\/li><li>Reviparin (theoretical)<\/li><li>Rivaroxaban (theoretical)<\/li><li>Rofecoxib (theoretical)<\/li><li>Salicylic Acid (theoretical)<\/li><li>Salsalate (theoretical)<\/li><li>Sertraline (probable)<\/li><li>Sodium Salicylate (theoretical)<\/li><li>Sulindac (theoretical)<\/li><li>Tenoxicam (theoretical)<\/li><li>Tiaprofenic Acid (theoretical)<\/li><li>Tinzaparin (theoretical)<\/li><li>Tolfenamic Acid (theoretical)<\/li><li>Tolmetin (theoretical)<\/li><li>Valdecoxib (theoretical)<\/li><li>Venlafaxine (probable)<\/li><li>Vilazodone (theoretical)<\/li><li>Vortioxetine (theoretical)<\/li><li>Warfarin (theoretical)<\/li><\/ul>"},{"id":"jtims4b15","title":"Moderate","mono":"<ul>Vitamin A (probable)<\/ul>"}]},"5":{"id":"jtims5","title":"Adverse Effects","mono":"<b>Common<\/b><ul><li><b>Cardiovascular:<\/b>Bradyarrhythmia (4%)<\/li><li><b>Hematologic:<\/b>Bleeding, Minor (10.5%)<\/li><li><b>Reproductive:<\/b>Pain in pelvis (6%)<\/li><\/ul><b>Serious<\/b><ul><li><b>Cardiovascular:<\/b>Dissecting aneurysm of coronary artery (5%)<\/li><li><b>Hematologic:<\/b>Bleeding, Major (1.4%), Thrombocytopenia (up to 1.5%)<\/li><li><b>Immunologic:<\/b>Anaphylaxis, Hypersensitivity reaction<\/li><li><b>Neurologic:<\/b>Intracranial hemorrhage<\/li><li><b>Respiratory:<\/b>Pulmonary hemorrhage<\/li><\/ul>"},"6":{"id":"jtims6","title":"Drug Name Info","sub":{"0":{"id":"jtims6b17","title":"US Trade Names","mono":"Aggrastat<br\/>"},"2":{"id":"jtims6b19","title":"Class","mono":"<ul><li>Glycoprotein IIb\/IIIa Inhibitor<\/li><li>Platelet Aggregation Inhibitor<\/li><\/ul>"},"3":{"id":"jtims6b20","title":"Regulatory Status","mono":"RX<br\/>"},"4":{"id":"jtims6b21","title":"Generic Availability","mono":"No<br\/>"}}},"7":{"id":"jtims7","title":"Mechanism Of Action","mono":"Tirofiban hydrochloride, a non-peptide platelet glycoprotein (GP) antagonist, inhibits aggregation of platelets by reversibly antagonizing fibrinogen binding to the GP IIb\/IIIa receptor.<br\/>"},"8":{"id":"jtims8","title":"Pharmacokinetics","sub":{"1":{"id":"jtims8b24","title":"Distribution","mono":"<ul><li>Vd: 22 L to 42 L<\/li><li>Protein binding: 35% unbound<\/li><\/ul>"},"2":{"id":"jtims8b25","title":"Metabolism","mono":"limited <br\/>"},"3":{"id":"jtims8b26","title":"Excretion","mono":"<ul><li>Fecal: 25% unchanged<\/li><li>Renal: 65% unchanged<\/li><li>Dialyzable: yes (hemodialysis)<\/li><\/ul>"},"4":{"id":"jtims8b27","title":"Elimination Half Life","mono":"approximately 2 h <br\/>"}}},"9":{"id":"jtims9","title":"Administration","mono":"<ul><li><b>General Information<\/b><br\/>for IV administration only<br\/><\/li><li><b>Intravenous<\/b><br\/><ul><li>do not add other drugs or remove solution directly from bag with syringe<\/li><li>do not use plastic containers in series connections.<\/li><li>discard any unused solution<\/li><\/ul><\/li><\/ul>"},"10":{"id":"jtims10","title":"Monitoring","mono":"<ul><li>reduced incidence of thrombotic cardiovascular events, including myocardial infarction, refractory ischemia, or repeat cardiac procedures, is indicative of efficacy<\/li><li>platelet count, 6 hours after treatment initiation, and at least daily during therapy<\/li><\/ul>"},"11":{"id":"jtims11","title":"How Supplied","mono":"<b>Aggrastat<\/b><br\/>Intravenous Solution: 0.05 MG\/ML<br\/>"},"13":{"id":"jtims13","title":"Clinical Teaching","mono":"<ul><li>Instruct patient to report signs\/symptoms of bleeding or bruising.<\/li><li>Side effects may include pelvic pain, leg pain, dizziness, edema\/swelling, and sweating.<\/li><li>Advise patient that there are multiple significant drug-drug interactions for this drug. Consult healthcare professional prior to new drug use (including over-the-counter and herbal drugs).<\/li><\/ul>"}}}